- GlobeNewswire•22 days ago
Sunesis Pharmaceuticals Announces Presentation of The Ohio State University-Sponsored Preclinical Study of BTK Inhibitor SNS-062 at AACR Annual Meeting
SOUTH SAN FRANCISCO, Calif., April 03, 2017-- Sunesis Pharmaceuticals, Inc. today announced results from an Ohio State University-sponsored preclinical study evaluating the efficacy of non-covalent BTK ...
- GlobeNewswire•28 days ago
SOUTH SAN FRANCISCO, Calif., March 28, 2017-- Sunesis Pharmaceuticals, Inc. today announced that Eric Bjerkholt, Executive Vice President Corporate Development and Finance and Chief Financial Officer of ...
- GlobeNewswire•last month
Sunesis Pharmaceuticals Announces Submission of Responses to the EMA Day 180 List of Outstanding Issues for Marketing Authorization Application for Vosaroxin
SOUTH SAN FRANCISCO, Calif., March 22, 2017-- Sunesis Pharmaceuticals, Inc. today announced that it has submitted its responses to the European Medicine Agency Day 180 List of Outstanding Issues issued ...
SNSS : Summary for Sunesis Pharmaceuticals, Inc. - Yahoo Finance
Sunesis Pharmaceuticals, Inc. (SNSS)
NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
|Bid||2.70 x 300|
|Ask||39.80 x 100|
|Day's Range||3.65 - 3.89|
|52 Week Range||2.64 - 6.30|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-1.55|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|